Intravesical treatment of bladder cancer: Current problems and needs

Urologia Internationalis

Volumn 61, Issue 4, 1998, Pages 199-205

  Schmitz Dräger, Bernd J ^a,c   Müller, Mirko ^b  

^a Urologie   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c Urologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; CYTOKINE; DOXORUBICIN; INTERFERON; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; MITOMYCIN C;

BLADDER CANCER; CANCER GROWTH; CANCER RECURRENCE; CARCINOMA IN SITU; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; IMMUNOTHERAPY; INTRAVESICAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVESICAL; ANIMALS; BCG VACCINE; CARCINOMA IN SITU; CLINICAL TRIALS; FEMALE; HUMANS; MALE; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 0032459433     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030329     Document Type: Review

References (63)

1. Lutzeyer W, Rübben H, Dahm H: Prognostic parameters in superficial bladder cancer: An analysis of 315 cases. J Urol 1982;127: 250-252.
2. Brosman SA: Experience with bacillus Calmette-Guérin in patients with superficial bladder carcinoma. J Urol 1982;128:27-30.
3. Lamm DL, Reichert DF, Harris SC, Lucio RM: Immunotherapy of transitional cell carcinoma. J Urol 1982;128:1106-1110.
4. Morales A, Eidinger D, Bruce AW: Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 1976; 116:18-21.
5. Hudson MA, Brown EJ, Ritchey JK, Ratliff TL: Modulation of fibronectin-mediated bacillus Calmette-Guérin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res 1991;51:3726-3732.
6. Hudson MA, Catalona WJ, Ritchey JK, Aslanzadeh J, Brown EJ, Ratliff TL: Comparison of the fibronectin-binding ability and antitumor efficacy of various mycobacteria. Cancer Res 1990;50:3843-3847.
7. Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL: Fibronectin-mediated Calmette-Guérin bacillus attachment to murine bladder mucosa: Requirement of the expression of an antitumor response. J Clin Invest 1990;85:62-67.
8. Kavoussi LR, Torrence RJ, Gillen DP, Hudson MA, Haaf EO, Dresner SM, Ratliff TL, Catalona WJ: Results of 6 weekly intravesical bacillus Calmette-Guérin instillations on the treatment of superficial bladder tumors. J Urol 1988; 139:935-940.
9. Ratliff TL, Kavoussi LR, Catalona WJ: Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J Urol 1988;139: 410-414.
10. Böhle A, Gerdes J, Ulmer AJ, Hofstetter A, Flad H-D: Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 1990;144:53-58.
11. Ratliff TL, Ritchey JK, Yuan JJJ, Andriole GL, Catalona WJ: T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 1993;150:1018-1023.
12. Böhle A, Nowc CH, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG, Flad H-D: Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy. J Urol 1990;144:59-64.
13. De Reijke TM, De Boer EC, Kurth K-H, Schamhart DHJ: Urinary cytokines during intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer: Processing, stability and prognostic value. J Urol 1996;155: 477-482.
14. Haaff EO, Catalona WJ, Ratliff TL: Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol 1986;136:970-974.
15. De Boer EC, Somogyi L, de Ruiter GJW, de Reijke TM, Kurth KH, Schamhart DHJ: Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol Res 1997;25:31-34.
16. Thalmann GN, Dewald B, Baggiolini M, Studer E: Interleukin-8 expression in the urine after bacillus Calmette-Guérin therapy: A potential prognostic factor of tumor recurrence and progression. J Urol 1997;158:1340-1344.
17. Haaff EO, Dresner SM, Ratliff TL, Catalona WJ: Two courses of intravesical bacillus Calmette-Guérin for transitional cell carcinoma of the bladder. J Urol 1986;136:820-824.
18. Jackson AM, Lien E, Alexandroff AB, Prescott S, Espevik T, James K, Selby PJ, Sundan A: Soluble urinary CD14 after intravesical Bacille Calmette-Guérin immunotherapy for carcinoma in situ. Br J Urol 1997;80:766-771.
19. Kavoussi LR, Torrence RJ, Gillen DP, Hudson MA, Haaf EO, Dresner SM, Ratliff TL, Catalona WJ: Results of 6 weekly intravesical bacillus Calmette-Guérin instillations on the treatment of superficial bladder tumors. J Urol 1988; 139:935-940.
20. Reitsma DJ: Long-term effect of intravesical Calmette-Guérin (BCG) Tice strain on flat carcinoma in situ of the bladder; in Debruyne FMJ, Denis L, van der Meijden APM (eds): BCG in Superficial Bladder Cancer. New York, Liss, 1989, pp 271-274.
21. Enderli JB, Merz V, Studer UE: Expérience clinique avec le traitement par instillation endovésicale du Bacille de Calmette-Guérin des tumeurs superficielles de la vessie. Méd Hyg 1989;47:3510-3512.
22. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossmann HB, Stanisic TH, Smith JA, Sullivan J, Sarosdy MF, Crissman JD, Coltman CA: A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guérin for transitional cell carcinoma of the bladder. N Engl J Med 1991;325:1205-1209.
23. Lamm DL, Crissman J, Blumenstein B, Crawford E, Montie J, Scardino P, Grossman HB, Stanisic T, Smith J, Sullivan J, Sarosdy M: Adriamycin versus BCG in superficial bladder cancer: A Southwest Oncology Group study; in Debruyne FMS, Denis L, van der Meijden APM (eds): BCG in Superficial Bladder Cancer. New York, Liss, 1989, pp 263-270.
24. Lamm DL, Crawford ED, Blumenstein BA, Crissman JD, Montie JE, Gottesman J, Lowe BA, Sarosdy MF, Bohl RD, Weems WL, Grossman HB, Smith JA, Beck TM, Leimert J, Coltman CA: Maintenance BCG immunotherapy of superficial bladder cancer: A randomized prospective Southwest Oncology Group study (abstract). J Urol 1992;147:242.
25. Harland SJ, Charig CR, Highman W, Parkinson MC, Riddle PR: Outcome in carcinoma in situ of bladder treated with intravesical Bacille Calmette-Guérin. Br J Urol 1992;70:271-275.
26. Herr HW: Intravesical BCG: Current results, natural history, and implications for urothelial cancer prevention. J Cell Biochem 1992; 161(suppl):112-119.
27. Herr HW, Laudone VP, Badalament RA: BCG therapy alters the progression of superficial bladder cancer. J Urol 1989;141:26-30.
28. Herr HW, Schwalb DM, Zhang ZF, Sogani PC, Fair WR, Whitmore WF, Oettgen HF: Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial. J Clin Oncol 1995;13:1404-1408.
29. Lamm DL: Bacillus Calmette-Guérin immunotherapy for bladder cancer. J Urol 1985;134: 40-47.
30. Lamm DL: Fortschritte in der Behandlung des oberflächlichen Harnblasenkarzinoms mit BCG-Immunotherapie: Ergebnisse kontrollierter nordamerikanischer Studien; in Böhle A, Jocham D (eds): BCG-Therapie des oberflächlichen Harnblasenkarzinoms: Bestandsaufnahme aus Klinik und Praxis. Berlin, Springer, 1994, pp 12-28.
31. Martinez-Pineiro JA, Jimenez Leon J, Martinez-Pineiro L, Fiter L, Mosteiro JA, Navarro J, Garcia Matres MJ, Carcamo P: Bacillus Calmette-Guérin versus doxorubicin versus thiotepa: A randomized prospective study in 202 patients with superficial bladder cancer. J Urol 1990;143:502-506.
32. Jauhiainen K, Rintala E, Alfthan O, Finnbladder Group: Immunotherapy (BCG) versus chemotherapy (MMC) in intravesical treatment of superficial urinary bladder cancer; in de Ker-nion JD (ed): Immunotherapy of Urological Tumors. London, Churchill Livingstone, 1990, pp 13-26.
33. Rintala E, Jauhiainen K, Alfthan O, Hansson E, Juusela H, Kanerva K, Korhonen H, Permi J, Stoarauta M, Vaalasti T, Viitanen J, Usenius R: Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer. Eur Urol 1991; 20:19-25.
34. Debruyne FMJ, van der Meijden APM, Franssen MP: BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. Prog Clin Biol Res 1992;303: 8912.
35. Debruyne FMJ, van der Meijden APM, Witjes JA, Franssen MPH, Steerenberg PA, De Jong WH, Read J, van Leeuwen MJW, Hammond B, Sylvester R: Bacillus Calmette-Guérin versus mitomycin intravesical therapy in superficial bladder cancer. Urology 1992;40(suppl):11-15.
36. Bassi P, Milani C, Meneghini A, Maruzzi D, Voltolina F, Drago Ferrante G, Piazza N, Tasca A, Piazza R, Banzato D, Garbeglio A: Bacillo di Calmette-Guérin a basso dosaggio e mitomicina C nel trattamento topico de carcinoma in situ della vescica: Risultati preliminari. Acta Urol ital, in press.
37. Krege S, Rübben H, Members of the Registry of Urinary Tract Tumors: Prospective randomized study of adjuvant therapy after complete resection of superficial bladder cancer: Mitomycin C vs. BCG Connaught vs. TUR alone (abstract). J Urol 1991;145:426.
38. Krege S, Giani G, Meyer R, Otto T, Rübben H: A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: Transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guérin Connaught. J Urol 1996;156:962-966.
39. Lundholm C, Norlén BJ, Ekman P, Jahnson S, Lagerkvist M, Lindeborg T, Olsson JL, Tveter K, Wijkström H, Westberg R, Malmström PU: A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma. J Urol 1996;156:372-376.
40. Kurth KH, Denis L, Bouffioux C, Sylvester R, Debruyne FMJ, Pavone-Macaluso M, Oosterlinck W: Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 1995;31:1840-1846.
41. Lamm DL, Riggs DR, Traynelis CL, Nseyo UO: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 1995;153: 1444-1450.
42. Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Meijden A, Parmar MKB, Bijnens L, Members of the EORTC, Cancer Cooperative Group, Medical Research Council Working Party on Superficial Bladder Cancer: A combined analysis of EORTC and Medical Research Council randomized clinical trials for the prophylactic treatment of stage Ta Tl bladder cancer. J Urol 1996;156:1934-1941.
43. Pagano F, Bassi P, Milani C, Meneghini A, Maruzzi D, Garbeglio A: A low dose bacillus Calmette-Guérin regimen in superficial bladder cancer therapy: Is it effective? J Urol 1991; 146:32-35.
44. Pagano F, Bassi P, Piazza N, Abatangelo G, Drago Ferrante GL, Milani C: Improving the efficacy of BCG immunotherapy by dose reduction. Eur Urol 1995;27(suppl 1):19-22.
45. Badalament RA, Herr HW, Wong GY, Gnecco C, Pinsky CM, Whitmore WF, Fair WR, Oettgen HF: A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. J Clin Oncol 1987;5:441-449.
46. Lamm DL, Sarosdy MF, Grossman HB, Bohl RD, Hatch T, Moon TD, Crawford ED, Lowe BA, Weems WL, Blumenstein B, Crissman J, Beck TM, Montie J, Smith JA: Maintenance vs. nonmaintenance BCG immunotherapy of superficial bladder cancer: A Southwest Oncology Group study (abstract). J Urol 1990;143: 341.
47. Morales A, Nickel JC, Wilson JWL: Dose-response of bacillus Calmette-Guérin in the treatment of superficial bladder cancer. J Urol 1992;157:1256-1258.
48. Melekos MD, Chionis H, Pantazakos A, Fokaefs E, Paranychianakis G, Dauaher H: Intravesical bacillus Calmette-Guérin immunoprophylaxis of superficial bladder cancer: Results of a controlled prospective trial with modified treatment schedule. J Urol 1993; 149:744-748.
49. Martinez-Pineiro JA, Solsona E, Flores N, Isorna S: Improving the safety of BCG immunotherapy by dose reduction. Eur Urol 1995; 27(suppl 1):13-18.
50. Caliskan M, Türkeri LN, Mansuroǧlu B, Toktas G, Aksoy B, Ünlüer E, Akdas A: Nuclear accumulation of mutant p53 protein: A possible predictor of failure of intravesical therapy in bladder cancer. Br J Urol 1997;79:373-377.
51. Ackermann D, Biedermann C, Bailly G, Studer UE: Treatment of superficial tumors of the bladder with bacillus Calmette-Guérin. J Urol (Paris) 1986;92:33-38.
52. Glashan RW: A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol 1990;144:658-661.
53. Grainger R, Donovan MG, O'Brien A, Hegarty JH, Butler MR, Fitzpatrick JM: Results of a prospective randomized study of the treatment of superficial bladder cancer using intravesical BCG and alpha 2b interferon (abstract). J Urol 1988;139:319.
54. Schmitz-Dräger BJ, Ebert T, Ackermann R: Intravesical treatment of superficial bladder carcinoma with interferons. World J Urol 1986; 3:218-223.
55. Torti FM, Lum BL: Superficial bladder cancer: Risk of recurrence and potential role for interferon therapy. Cancer 1987;59(suppl 3): 613-616.
56. Torti FM, Shortliffe LD, Williams RD, Pitts WC, Kempson RL, Ross JC, Palmer J, Meyers F, Ferrari M, Hannigan J: Alpha-interferon in superficial bladder cancer: A Northern California Oncology Group study. J Clin Oncol 1988;6:476-483.
57. Williams RD: Intravesical interferon alpha in the treatment of superficial bladder cancer. Semin Oncol 1988;15(suppl 5):10-13.
58. Niijima T: Intravesical treatment of bladder cancer with recombinant human interferon-β. Cancer Immunol Immunother 1989;30:81-85.
59. Boccardo F, Guiliani L: Prophylaxis of superficial bladder cancer with mitomycin or interferon alpha-2b: Results of a multicentric Italian study. J Clin Oncol 1994;12:7-13.
60. Huland E, Huland H: Local continuous high dose interleukin 2: A new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res 1989;49:5469-5474.
61. Olsson CA, Chute R, Rao CN: Immunological reduction of bladder cancer recurrence rates. J Urol 1974;111:173-175.
62. Jurincic CD, Engelmann U, Gasch J, Klippel KF: Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: A randomized study. J Urol 1988;139:723-726.
63. Kälble T, Möhring K, Ikinger ZU, Riedasch G, Staehler G: Intravesikale Rezidivprophylaxe beim oberflächlichen Harnblasenkarzinom mit BCG und KLH. Urologe A 1991;30:118-121.